US3467756A - Composition and method for treating glaucoma - Google Patents
Composition and method for treating glaucoma Download PDFInfo
- Publication number
- US3467756A US3467756A US623540A US3467756DA US3467756A US 3467756 A US3467756 A US 3467756A US 623540 A US623540 A US 623540A US 3467756D A US3467756D A US 3467756DA US 3467756 A US3467756 A US 3467756A
- Authority
- US
- United States
- Prior art keywords
- glaucoma
- epoxy
- opthalmic
- hydroxyimino
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Definitions
- the present invention relates to topical opthalmic compositions useful in the treatment of glaucoma. More particularly, this invention relates to anti-glaucoma agents which effectively lower intraocular pressure and to methods for the preparation and administration of such compositions.
- a further object is to topically administer such compositions to the eye in a dosage form that will significantly lower intraocular pressure while achieving the pupillary goals of a submaximally dilated and mobile pupil, retaining sensitivity to stimulation by light.
- compositions of this invention contain one of the following compounds as novel intraocular hypotensive agents:
- compositions of this invention wherein the novel hypotensive agents form the only active ingredient effectively lower intraoclar tension for some purposes it may be desirable to combine treatment with exogenous sympathomirnetic amines.
- the sympathomimetic amine can be administered with the intraocular hypotensive agent of this invention in a single vehicle in dosages which effectively lower intraocular pressure.
- exemplary of such sympathomimetic amines are epinephrine, norepinephrine and isoproterenol.
- the sympathomimetic amine can be administered following instillation of the novel hypotensive agent of this invention.
- compositions of this invention are administered topically to the eye, either in the form of opthalmic solutions, or as opthalmic ointments.
- Formulations are herein expressed as percent weight by volume and generally the dosages for the intraocular hypotensive agent fall within the range of 0.01 to 0.02 percent. Higher dosages, as for example, up to about 0.2 percent, or lower dosages can be employed, provided the dose is effective in lowering intraocular pressure, is non-irritating and achieves the desired pupillary goals previously set forth.
- compositions of this invention are incorporated into a sterile opthalmic vehicle.
- sterile opthalmic vehicles are Well known in the art and are fully described in such standard reference works as Remingtons Pharmaceutical Sciences, Martin and Cook, Mack Publishing Co., Easton, 13th 3 edition (1965). The following is a suitable example. (The percentages in the following examples refer to a percent weight by volume.)
- the 8-hydroxyquinolone and the sodium bisulfite act as anti-oxidants and can vary tenfold (the former up to about 0.1% and the latter down to about 0.03%.)
- any opthalmic anti-oxidant can be employed. These are more fully described in Remington (supra).
- Phenyl mercuric acetate is employed as a preservative. Any preservative suitable for opthalmic formulation such as those described in Remington (supra) can be employed.
- pH of the foregoing sterile vehicle is adjusted using base or acid it should be recognized that standard buffering agents such as those described in Remington (supra) or in the Merck Index, volume 7 (1960), so long as these buffering agents are suitable for opthalmic formulation, can be utilized. Thus a pH range from about 3.5-8 can be employed, although pH within the physiological range is preferred. When employing a buffered system it is preferred to utilize a pH of about 6.0 to about 8. With a buffered system pH is conventionally adjusted by adjusting the concentration and at the time altering the ratio of the buffered tonicity so as to maintain an isotonic solution.
- buffers can be used at varying pH, when pH is less than 6.0, sodium hydroxide or hydrochloric acid can conveniently be employed to adjust the pH. When using a buffered system it is preferred to adjust the range to that of the physiological pH range of about 6 to 7.5 or 8. US. Patent 3,149,035 sets forth suitable sterile vehicles for use, especially when a catechol amine, such as epinephrine, is employed in the compositions of this invention.
- compositions of this invention can also be administered as opthalmic ointments. These are compounded, for example, by mixing finely milled powdered ingredients with a small amount of white petrolatum and levigating or otherwise mixing until a uniform distribution is achieved. The balance of white petrolatum is added by geometric addition until the desired dosage form is made.
- An anti-glaucoma topical opthalmic composition comprising a topical opthalmic vehicle and 0.01 to 0.2% of a member selected from the group consisting of 10,11- dihydro 5 (3-dimethylaminopropyl)-5,10-epoxy-5H-dibenzo[a,d]cycloheptene-1l-hydroxy-imino, trans 10,1 1-dihydro 5-(3-methylaminopropyl)-5,10-epoxy-1l-hydroxy- 5H-dibenzo[a,d]cycloheptene and a non-toxic acid addition salt thereof.
- a method for lowering intraocular pressure which comprises applying topically to the eye an effective amount of a composition comprising a topical opthalmic vehicle and 0.01 to 0.2% of a member selected from the group consisting of 10,11 dihydro-5-(3-dimethylaminopropyl)- 5,10 epoxy 5H-dibenzo[a,d]cycloheptene-ll-hydroxyimino, trans 10,11 dihydro-5-(3-methylaminopropyl)-5, 10 epoxy-11-hydroxy-5H-dibenzo[a,d]cycloheptene and a non-toxic acid addition salt thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62354067A | 1967-03-16 | 1967-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
US3467756A true US3467756A (en) | 1969-09-16 |
Family
ID=24498471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US623540A Expired - Lifetime US3467756A (en) | 1967-03-16 | 1967-03-16 | Composition and method for treating glaucoma |
Country Status (8)
Country | Link |
---|---|
US (1) | US3467756A (fr) |
BE (1) | BE712259A (fr) |
DE (1) | DE1667898A1 (fr) |
FR (1) | FR7841M (fr) |
GB (1) | GB1174882A (fr) |
IE (1) | IE31971B1 (fr) |
IL (1) | IL29570A (fr) |
NL (1) | NL6802823A (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993018762A2 (fr) | 1992-03-19 | 1993-09-30 | Allergan, Inc. | Procede de reduction de la pression intraoculaire chez les mammiferes par l'administration d'agonistes d'acide gamma-aminobutyrique (gaba) |
US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
US5891911A (en) * | 1995-07-28 | 1999-04-06 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators |
US6350780B1 (en) | 1995-07-28 | 2002-02-26 | Allergan Sales, Inc. | Methods and compositions for drug delivery |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3264342A (en) * | 1963-05-24 | 1966-08-02 | Geigy Chem Corp | Derivatives of 5h-dibenzo[a, d] cycloheptene |
US3336340A (en) * | 1963-11-29 | 1967-08-15 | Rohm & Haas | Benzopyrans and process for the preparation thereof |
-
1967
- 1967-03-16 US US623540A patent/US3467756A/en not_active Expired - Lifetime
-
1968
- 1968-02-28 NL NL6802823A patent/NL6802823A/xx unknown
- 1968-03-04 IL IL29570A patent/IL29570A/en unknown
- 1968-03-04 IE IE249/68A patent/IE31971B1/xx unknown
- 1968-03-12 GB GB01980/68A patent/GB1174882A/en not_active Expired
- 1968-03-15 BE BE712259D patent/BE712259A/xx unknown
- 1968-03-15 FR FR144115A patent/FR7841M/fr not_active Expired
- 1968-03-15 DE DE19681667898 patent/DE1667898A1/de active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3264342A (en) * | 1963-05-24 | 1966-08-02 | Geigy Chem Corp | Derivatives of 5h-dibenzo[a, d] cycloheptene |
US3336340A (en) * | 1963-11-29 | 1967-08-15 | Rohm & Haas | Benzopyrans and process for the preparation thereof |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716952A (en) * | 1992-03-18 | 1998-02-10 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
WO1993018762A2 (fr) | 1992-03-19 | 1993-09-30 | Allergan, Inc. | Procede de reduction de la pression intraoculaire chez les mammiferes par l'administration d'agonistes d'acide gamma-aminobutyrique (gaba) |
US6077839A (en) * | 1992-03-19 | 2000-06-20 | Allergan Sales, Inc. | Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists |
US5891911A (en) * | 1995-07-28 | 1999-04-06 | Allergan | Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators |
US6350780B1 (en) | 1995-07-28 | 2002-02-26 | Allergan Sales, Inc. | Methods and compositions for drug delivery |
Also Published As
Publication number | Publication date |
---|---|
IE31971L (en) | 1968-09-16 |
BE712259A (fr) | 1968-09-16 |
DE1667898A1 (de) | 1971-07-22 |
IL29570A (en) | 1971-07-28 |
FR7841M (fr) | 1970-05-25 |
IE31971B1 (en) | 1973-03-07 |
GB1174882A (en) | 1969-12-17 |
NL6802823A (fr) | 1968-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100365914B1 (ko) | 점도가감소된안약조성물 | |
KR101160780B1 (ko) | Rho 키나아제 억제제 및 프로스타글란딘류를 포함하는 녹내장 치료제 | |
EP0389995B1 (fr) | Dérivés de l'isoquinoléine pour le traitement de glaucome ou de l'hypertension oculaire | |
JP4934653B2 (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
JPS6322021A (ja) | 眼圧制御剤 | |
US4275074A (en) | Catecholamine treatment of ocular hypertension | |
US5182102A (en) | Anti-glaucoma compositions | |
US5705510A (en) | Use of cabergoline and related ergoline derivatives for controlling intraocular pressure | |
US3467756A (en) | Composition and method for treating glaucoma | |
GB2042338A (en) | Composition for treating glaucoma | |
EP0724443A1 (fr) | Procedes et comositions d'abaissement de la pression intra-oculaire | |
JPH10324640A (ja) | 炭酸脱水酵素阻害剤およびβ遮断剤を含有する局所用抗緑内障組成物 | |
US3920824A (en) | Stable ophthalmic formulation | |
US3644647A (en) | Treatment of glaucoma employing 5-(3-methylaminopropyl - 5h - dibenzo(a b) cycloheptene | |
RU2218156C2 (ru) | Способ изготовления состава местных бета-блокаторов улучшенного действия | |
PL172503B1 (pl) | Oftalmiczny srodek do podawania miejscowego zawierajacy pólwodzian (S)-tymololu PL PL PL PL | |
EP0140789A2 (fr) | Utilisation d'antagonistes de dopamine périphérique sélectifs pour la fabrication d'un médicament pour le traitement topique de l'hypertension oculaire | |
EP0728480A1 (fr) | Utilisation d'ifenprodil pour le traitement de la pression intraoculaire élevée | |
RU2100020C1 (ru) | Средство для местного лечения глазной гипертензии и глаукомы и способ его получения | |
JPH03106816A (ja) | 緑内障治療用点眼剤 | |
US3888985A (en) | Method and composition for lowering intraocular pressure | |
US3888991A (en) | Method and composition for lowering intraocular pressure | |
KR20210143254A (ko) | 마취 조성물 및 안구의 마취 방법 | |
JPH04134029A (ja) | 緑内障治療剤 | |
EP0606393A1 (fr) | Compositions ophtalmiques topiques comprenant des 4-(3-amino substitue-2-hydroxypropoxy)-1,2,5-thiadiazoles, et procedes d'utilisation de ces compositions |